Skip to main content
Abstracts

Cost and Cost per Patient Achieving Key Clinical Outcomes With Perioperative Durvalumab Plus Chemotherapy Versus Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Citation:

2564715

Background

To compare the costs and cost per clinical outcome achieved for perioperative durvalumab plus neoadjuvant gemcitabine/cisplatin (durvalumab + GC) vs perioperative enfortumab vedotin plus intravenous pembrolizumab (EVP) among patients with cisplatin-eligible muscle-invasive bladder cancer.

Methods

A decision-tree model estimated costs and outcomes from a U. all-payer perspective over a 2-year time horizon. Event-free survival (EFS) and overall survival (OS) were derived from published NIAGARA and EV-304 trial data using an unadjusted cross-trial comparison. No formal indirect treatment comparison or network meta-analysis was conducted. Durvalumab + GC Kaplan-Meier outcomes were observed through 60 months.

EVP outcomes were observed through 58 months and extrapolated to month 60 using log-normal and exponential models for EFS and OS, respectively, selected based on statistical fit and visual agreement with the observed curves. Costs included treatment acquisition and administration, surgery, adverse-event management, disease-management, and patient travel.

Disease-management costs included event-free care, post-event/recurrence care, and terminal care during the final 30 days of life. Surgery costs included both the initial radical cystectomy and any readmissions within 90 days after cystectomy. Drug acquisition costs were based on wholesale acquisition cost from RED BOOK across allpayer types. Costs were reported in 2026 US dollars and discounted at 3% annually.

Outcomes included total cost per patient, between-regimen cost differences, expected EFS and OS months, and costs per event-free or surviving patient at 2 years. Cost per event-free patient and cost per surviving patient were calculated by dividing cumulative 2-year total cost per patient by the corresponding trial-reported EFS and OS probabilities.

Results

Cumulative total costs at 2 years were $153 341 (31.1%) lower for durvalumab + GC ($339 366) compared to EVP ($492 707). The higher cost of EVP was driven by differences in treatment-acquisition costs ($147 470 for durvalumab + GC vs $31 ,428 for EVP) and only partially offset by differences in disease-management costs (durvalumab + GC: $140 174 vs EVP: $126 668) with all other costs largely similar. Trial-reported 2-year EFS rates were 67.8% and 79.4%, and OS rates were 82.2% and 86.9%, for durvalumab + GC and EVP, respectively. At 2 years, cost per event-free patient was $500 540 for durvalumab + GC and $620 538 for EVP, a difference of -$119 998. Cost per surviving patient was $412 854 and $566 982, respectively, a difference of -$154 128. At 2 years, the unadjusted trial-reported survival curves yielded expected EFS of 18.89 months for durvalumab + GC and 21.03 months for EVP, and expected OS of 21.64 months and 22.28 months, respectively. Median follow-up was 42.3 months in NIAGARA and 33.6 months in KEYNOTE-B15/EV-304, exceeding the primary 24-month analytic horizon. Therefore, no survival extrapolation was required for the 2-year analysis.

Conclusion

Over a 2-year horizon, perioperative durvalumab + GC was associated with substantially lower total costs than EVP, largely due to lower treatment acquisition costs. When total treatment costs were contextualized against unadjusted trial-reported 2-year outcomes, durvalumab + GC demonstrated lower costs per patient achieving key clinical outcomes.

These findings provide descriptive economic context that may help inform treatment choice among available perioperative options for cisplatin-eligible patients with muscle-invasive bladder cancer.

Click here to view the poster.

Author Information

Authors:

Shanshan Wang1; Jason Shafrin, PhD1; Moises Marin1; Simran Shokar, MPH2; Leana Bellanca2; Etkin Gurcan2; Benjamin Garmezy, MD3

Affiliations:

1FTI Consulting; 2AstraZeneca; 3Sarah Cannon Research Institute

Sponsor:

AstraZeneca